Program
liposomal doxorubicin
Also written as “PLD”, “Doxorubicin Hydrochloride Liposome Injection” and “Pegylated liposomal doxorubicin”.
Its studies are mostly in Ovarian Neoplasms · Breast Neoplasms · Multiple Myeloma · Carcinoma, Ovarian Epithelial · Endometrial Neoplasms, led by 16 companies.
Drug pageLiposomal doxorubicin: every studyMany companies study it; this page follows only the 33 they lead. All 210 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 90 open or running | phase 3since Apr 29, 2004 | Apr 29, 2004 | none ahead |
| Merckits history only | 60 open or running | phase 4since Jan 21, 2008 | Dec 15, 2005 | none ahead |
| CSPC Pharmaceutical Groupits history only | 20 open or running | phase 2since Dec 11, 2017 | Dec 11, 2017 | none ahead |
| Imunonits history only | 20 open or running | phase 2since Nov 1, 2011 | Jun 5, 2003 | none ahead |
| Oncotherapeuticsits history only | 20 open or running | phase 2since Aug 26, 2008 | Aug 26, 2008 | none ahead |
| TTY Biopharmits history only | 20 open or running | phase 2since Aug 31, 2010 | Aug 31, 2010 | none ahead |
| Ayana Pharmaits history only | 10 open or running | phase 1since Sep 17, 2018 | Sep 17, 2018 | none ahead |
| Azaya Therapeuticsits history only | 10 open or running | phase 1since Oct 19, 2012 | Oct 19, 2012 | none ahead |
| Baxter Healthcareits history only | 10 open or running | phase 1since Sep 29, 2022 | Sep 29, 2022 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 10 open or running | phase 1since Sep 22, 2014 | Sep 22, 2014 | none ahead |
| Luye Pharma Groupits history only | 10 open or running | phase 1since Oct 18, 2023 | Oct 18, 2023 | none ahead |
| Sarah Cannon Research Instituteits history only | 10 open or running | phase 2since Mar 13, 2006 | Mar 13, 2006 | none ahead |
| Shanghai Fudan-Zhangjiang Bio-Pharmaceuticalits history only | 10 open or running | phase 1since Aug 31, 2014 | Aug 31, 2014 | none ahead |
| Shenzhen Kangzhe Pharmaceuticalits history only | 10 open or running | phase 1since Feb 10, 2022 | Feb 10, 2022 | none ahead |
| Takedaits history only | 10 open or running | phase 2since Jan 28, 2008 | Jan 28, 2008 | none ahead |
| Teva Pharmaceutical Industriesits history only | 10 open or running | phase 2since Jul 8, 2008 | Jul 8, 2008 | none ahead |
Also a collaborator on its studies: Eisai, Novotech (Australia) Pty, Lambda Therapeutic Research, MDS Pharma Services, Essex Pharma, Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA, Ortho Biotech, Tibotec Pharmaceutical, Sequus Pharmaceuticals and Prologue Research International.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 19 studies since Jun 5, 2003.
- Oct 11, 2011Phase 2 study in Breast NeoplasmsTTY Biopharm · NCT01451580 · 47 enrolled · Taiwan
- Nov 1, 2011Phase 2 study in Colonic NeoplasmsImunon · NCT01464593 · 2 enrolled · United States
- Oct 19, 2012Azaya Therapeutics’ first study: phase 1 study in Ovarian NeoplasmsNew to Azaya TherapeuticsAzaya Therapeutics · NCT01715168 · 40 enrolled · United States, Canada
- Mar 18, 2013Phase 3 study in Carcinoma, Ovarian EpithelialJohnson & Johnson · NCT01840943 · 32 enrolled · China
- Mar 5, 2014Phase 1 study in NeoplasmsJohnson & Johnson · NCT02081495 · 35 enrolled · United States, Belgium, Canada and more
- Jul 30, 2014Phase 2 study in Multiple MyelomaOncotherapeutics · NCT02206425 · 45 enrolled · United States
- Aug 31, 2014Shanghai Fudan-Zhangjiang Bio-Pharmaceutical’s first study: phase 1 study in Ovarian NeoplasmsNew to Shanghai Fudan-Zhangjiang Bio-PharmaceuticalShanghai Fudan-Zhangjiang Bio-Pharmaceutical · NCT02237690 · 30 enrolled · China
- Sep 22, 2014Dr. Reddy's Laboratories’ first study: phase 1 study in Ovarian Epithelial Cancer RecurrentNew to Dr. Reddy's LaboratoriesDr. Reddy's Laboratories · NCT02260544 · 49 enrolled · India
- Dec 11, 2017CSPC Pharmaceutical Group’s first study: phase 2 study in Poorly Differentiated Thyroid CarcinomaNew to CSPC Pharmaceutical GroupCSPC Pharmaceutical Group · NCT03387943 · 30 enrolled · China
- Sep 17, 2018Ayana Pharma’s first study: phase 1 study in Ovarian NeoplasmsNew to Ayana PharmaAyana Pharma · NCT03681548 · 52 enrolled · India
- Jul 2, 2020No phase study in BioequivalenceCSPC Pharmaceutical Group · NCT04460820 · 32 enrolled · China
- Feb 10, 2022Shenzhen Kangzhe Pharmaceutical’s first study: phase 1 study in Breast NeoplasmsNew to Shenzhen Kangzhe PharmaceuticalShenzhen Kangzhe Pharmaceutical · NCT05273944 · 80 enrolled · China
- Sep 29, 2022Baxter Healthcare’s first study: phase 1 study in Ovarian NeoplasmsNew to Baxter HealthcareBaxter Healthcare · NCT05567601 · 36 enrolled · India
- Oct 18, 2023Luye Pharma Group’s first study: phase 1 study in Advanced Breast CancerNew to Luye Pharma GroupLuye Pharma Group · NCT06098599 · 48 enrolled · China
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 33 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06098599Advanced Breast Cancer · China | 1 | Completed | Luye Pharma Group | Feb 9, 2023 | 48 |
| NCT05567601Ovarian Neoplasms · India | 1 | Completed | Baxter Healthcare | Jun 21, 2024 | 36 |
| NCT05273944Breast Neoplasms · China | 1 | UNKNOWN | Shenzhen Kangzhe Pharmaceutical | Mar 31, 2022 | 80 |
| NCT04460820Bioequivalence · China | – | Completed | CSPC Pharmaceutical Group | Dec 23, 2019 | 32 |
| NCT03681548Ovarian Neoplasms · India | 1 | Completed | Ayana Pharma | Feb 8, 2019 | 52 |
| NCT03387943Poorly Differentiated Thyroid Carcinoma · China | 2 | UNKNOWN | CSPC Pharmaceutical Group | Dec 31, 2018 | 30 |
| NCT02260544Ovarian Epithelial Cancer Recurrent · India | 1 | Completed | Dr. Reddy's Laboratories | Apr 2015 | 49 |
| NCT02237690Ovarian Neoplasms · China | 1 | Completed | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical | Aug 2015 | 30 |
| NCT02206425Multiple Myeloma · United States | 2 | Completed | Oncotherapeutics | Jan 19, 2018 | 45 |
| NCT02081495Neoplasms · United States, Belgium, Canada and more | 1 | Completed | Johnson & Johnson | Nov 2015 | 35 |
| NCT01840943Carcinoma, Ovarian Epithelial · China | 3 | Terminated | Johnson & Johnson | May 2014 | 32 |
| NCT01715168Ovarian Neoplasms · United States, Canada | 1 | UNKNOWN | Azaya Therapeutics | Oct 2015 | 40 |
| NCT01464593Colonic Neoplasms · United States | 2 | Terminated | Imunon | May 2013 | 2 |
| NCT01451580Breast Neoplasms · Taiwan | 2 | UNKNOWN | TTY Biopharm | 47 | |
| NCT01210768Breast Neoplasms · Taiwan | 2 | UNKNOWN | TTY Biopharm | Oct 31, 2022 | 254 |
| NCT00779285Breast Neoplasms | 4 | Terminated | Merck | Aug 2006 | 1 |
| NCT00742404Multiple Myeloma · United States | 2 | UNKNOWN | Oncotherapeutics | Jul 2010 | 35 |
| NCT00712881Breast Neoplasms · Austria, Belgium, France and more | 2 | Completed | Teva Pharmaceutical Industries | Sep 17, 2015 | 126 |
| NCT00706953Multiple Myeloma | 2 | Withdrawn | Johnson & Johnson | Jun 2010 | 0 |
| NCT00727961Ovarian Neoplasms | 4 | Completed | Merck | Jan 10, 2008 | 58 |
| NCT00698451Ovarian Neoplasms · United States | 2 | Completed | Johnson & Johnson | Oct 2010 | 54 |
| NCT00687440Breast Neoplasms | 2 | Completed | Merck | Oct 24, 2008 | 27 |
| NCT00653952Ovarian Neoplasms | 3 | Terminated | Johnson & Johnson | 220 | |
| NCT00610792Ovarian Neoplasms · Italy, Switzerland | 2 | Withdrawn | Takeda | Sep 2009 | 91 |
| NCT00604968Breast Neoplasms | 4 | Terminated | Merck | Oct 16, 2009 | 25 |
| NCT00561743Multiple Myeloma | 2 | Completed | Johnson & Johnson | May 2007 | 50 |
| NCT00550771Breast Neoplasms | 2 | Completed | Merck | Aug 23, 2010 | 181 |
| NCT00303108Breast Neoplasms · United States | 2 | Completed | Sarah Cannon Research Institute | Mar 2010 | 136 |
| NCT00266799Breast Neoplasms | 3 | Completed | Merck | Sep 29, 2010 | 210 |
| NCT00097981Multiple Myeloma · United States | 3 | Completed | Johnson & Johnson | Oct 2007 | 225 |
| NCT00091442Breast Neoplasms · United States, Bulgaria, Estonia and more | 3 | Completed | Johnson & Johnson | Dec 2008 | 751 |
| NCT00082095Breast Neoplasms · United States | 3 | Terminated | Johnson & Johnson | Dec 2005 | 62 |
| NCT00061867Prostatic Neoplasms · United States | 1 | Completed | Imunon |
How it is read
Names in the registry
- “PLD”, 4 entries
- “Doxorubicin Hydrochloride Liposome Injection”, 4 entries
- “Pegylated liposomal doxorubicin”, 3 entries
- “Pegylated Liposomal Doxorubicin (PLD)”, 2 entries
- “liposomal doxorubicin”, 2 entries
Conditions, from the studies’ own filings
- Ovarian Neoplasms, 16 studies
- Breast Neoplasms, 13 studies
- Multiple Myeloma, 5 studies
- Carcinoma, Ovarian Epithelial, 3 studies
- Endometrial Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.